Strensiq (Asfotase alfa)

Strensiq is a tissue nonspecific alkaline phosphatase and the only prescription medicine used to treat patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

Recommended Dosage: 

Dosage for Perinatal/Infantile-Onset HPP: The recommended dosage of Strensiq injection for treating perinatal/infantile-onset HPP is 6 mg/kg/weekly given subcutaneously as either 2 mg/kg three (3) times per week, or 1 mg/kg six (6) times per week. Injection site reactions may be responsible for limiting the tolerability of the six (6) times per week dosage regimen.

The dose of Strensiq may be scaled up for lack of efficacy up to 9 mg/kg per week given subcutaneously as 3 mg/kg three (3) times per week.

Dosage for Juvenile-Onset HPP: The recommended dosage of Strensiq for treating juvenile-onset HPP is 6 mg/kg/weekly given subcutaneously as either 2 mg/kg three (3) times weekly, or 1 mg/kg six (6) times weekly. Injection site reactions may be responsible for limiting the tolerability of the six times per week dosage regimen.

Caution: Avoid the use of Strensiq 80 mg/0.8 mL vial in those pediatric patients who weighing below 40 kg because the systemic exposure of asfotase alfa achieved with the Strensiq vial 80 mg/0.8 mL (greater concentration) is below that achieved with the other existing strength vials of Strensiq injection (reduced concentration). A reduced exposure may not be appropriate for this subgroup of patients. 

• Hypersensitivity reactions may occur in patients treated with Strensiq vials. In case of a severe hypersensitivity reaction, discontinue this treatment and initiate suitable medical treatment. In addition, patients must be precisely monitored for a reoccurrence of manifestations of a severe hypersensitivity reaction.
  
• Localized lipodystrophy, including lipohypertrophy and lipoatrophy, may occur at injection sites after some months in those treated with Asfotase alfa 18 mg/0.45 mL injection. Patients should follow appropriate injection techniques and rotate injection sites.
  
• Patients on therapy with HPP are at higher risk for having ectopic calcifications. Ophthalmology evaluations and renal ultrasounds are needed during treatment with Strensiq to monitor for manifestations of ophthalmic and renal ectopic calcifications and for alterations in vision or renal function.
  
• Strensiq injection is not recommended during pregnancy and in females who can have children and who are not considering appropriate contraception. Breastfeeding needs to be discontinued during therapy with Strensiq 18 mg/0.45 mL.
  

What documents are required to import STRENSIQ to India?

STRENSIQ (asfotase alfa) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)
  

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

STRENSIQ (asfotase alfa injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.
  

STRENSIQ can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of STRENSIQ (prescription medicines) to all places in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Strensiq 18 mg injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the STRENSIQ (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Strensiq®?

Asfotase alfa is a Generic Name for the trade name drug Strensiq®.

What is the Manufacturer’s Name of Strensiq®?

Strensiq® is manufactured by Alexion Pharmaceuticals, Inc.

Is Strensiq® approved by the FDA?

Yes, Strensiq® is approved by the FDA. Date of first/initial approval: October 23, 2015.

Where can I get Strensiq® at the best price in India?

To get the best Strensiq price in India, kindly get in touch with Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Strensiq®, a medical prescription is required from your treating physician.

What is the dosage and form of Strensiq® supplied?

Strensiq® is supplied as an Injection: 80 mg/0.8 mL, 40 mg/mL, 28 mg/0.7 mL, or 18 mg/0.45 mL solution in single-use vials for subcutaneous administration. 

What are the most common side effects of Strensiq®? 

The most common side effects of Strensiq are ectopic calcifications, lipodystrophy, hypersensitivity reactions, and injection site reactions.

How much does Strensiq cost in India?

The Strensiq cost in India can vary. In order to procure Strensiq legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Strensiq®?

Vials of Strensiq must be stored under refrigerated conditions at 2°C to 8°C (36°F to 46°F) in the original carton and protected from light. After removing from refrigeration, it should be administered within 60 minutes. Avoid freezing and shaking the vials.

Is it safe to buy Strensiq® online in India?

Yes, one can buy Strensiq in India at the best price from the Indian Pharma Network (IPN) if Strensiq has not been launched or is unavailable in the country. We can help facilitate the Import of Strensiq through legal channels.